Correlation Between Freeline Therapeutics and Opthea
Can any of the company-specific risk be diversified away by investing in both Freeline Therapeutics and Opthea at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Freeline Therapeutics and Opthea into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Freeline Therapeutics Holdings and Opthea, you can compare the effects of market volatilities on Freeline Therapeutics and Opthea and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Freeline Therapeutics with a short position of Opthea. Check out your portfolio center. Please also check ongoing floating volatility patterns of Freeline Therapeutics and Opthea.
Diversification Opportunities for Freeline Therapeutics and Opthea
-0.55 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Freeline and Opthea is -0.55. Overlapping area represents the amount of risk that can be diversified away by holding Freeline Therapeutics Holdings and Opthea in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Opthea and Freeline Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Freeline Therapeutics Holdings are associated (or correlated) with Opthea. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Opthea has no effect on the direction of Freeline Therapeutics i.e., Freeline Therapeutics and Opthea go up and down completely randomly.
Pair Corralation between Freeline Therapeutics and Opthea
If you would invest 257.00 in Opthea on September 12, 2024 and sell it today you would earn a total of 92.00 from holding Opthea or generate 35.8% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 0.41% |
Values | Daily Returns |
Freeline Therapeutics Holdings vs. Opthea
Performance |
Timeline |
Freeline Therapeutics |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Opthea |
Freeline Therapeutics and Opthea Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Freeline Therapeutics and Opthea
The main advantage of trading using opposite Freeline Therapeutics and Opthea positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Freeline Therapeutics position performs unexpectedly, Opthea can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Opthea will offset losses from the drop in Opthea's long position.Freeline Therapeutics vs. Cns Pharmaceuticals | Freeline Therapeutics vs. ZyVersa Therapeutics | Freeline Therapeutics vs. Immix Biopharma | Freeline Therapeutics vs. Hepion Pharmaceuticals |
Opthea vs. Molecular Partners AG | Opthea vs. MediciNova | Opthea vs. Anebulo Pharmaceuticals | Opthea vs. Champions Oncology |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Complementary Tools
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Fundamental Analysis View fundamental data based on most recent published financial statements |